Asterias Biotherapeutics (AST) Reports Top-Line 12-Month Data Update for OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Tweet Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST) today provided top-line 12 month data from the Company’s Phase 1/2a SCiStar study designed to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
